Login to Your Account



Versartis speeds somavaratan 'growth' prospects in Japan with Teijin Pharma deal

By Marie Powers
News Editor

Wednesday, August 10, 2016

Versartis Inc. lassoed its first commercial partner, Teijin Pharma Ltd., to develop and market its long-acting recombinant human growth hormone candidate, somavaratan (VRS-317), in Japan.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription